As an oncogenic driver of GBM, the expression of EGFR is upregulated during hypoxia, and the anti-EGFR antibody nimotuzumab exhibited beneficial effects for the survival of GBM patients [135]. This evidence concerns the gene EGFR and glioblastoma.